133 related articles for article (PubMed ID: 7941593)
21. Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.
Höchtl T; Horvath Z; Bauer W; Karl D; Saiko P; Elford HL; Fritzer-Szekeres M; Szekeres T
Life Sci; 2004 Jan; 74(9):1071-80. PubMed ID: 14687648
[TBL] [Abstract][Full Text] [Related]
22. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
[TBL] [Abstract][Full Text] [Related]
23. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
[TBL] [Abstract][Full Text] [Related]
24. Targeted and non-targeted actions of anti-cancer drugs.
Weber G; Prajda N
Adv Enzyme Regul; 1994; 34():71-89. PubMed ID: 7942286
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
Heinemann V; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
[TBL] [Abstract][Full Text] [Related]
26. Interaction between cisplatin and gemcitabine in vitro and in vivo.
Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
[TBL] [Abstract][Full Text] [Related]
27. Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells.
Ross DD; Cuddy DP
Biochem Pharmacol; 1994 Oct; 48(8):1619-30. PubMed ID: 7980627
[TBL] [Abstract][Full Text] [Related]
28. Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
Bader Y; Hartmann J; Horvath Z; Saiko P; Grusch M; Madlener S; Maier S; Oehler L; Fritzer-Szekeres M; Heller N; Alken RG; Krupitza G; Szekeres T
Cancer Lett; 2008 Feb; 259(2):231-9. PubMed ID: 18023527
[TBL] [Abstract][Full Text] [Related]
29. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
[TBL] [Abstract][Full Text] [Related]
30. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells.
Horvath Z; Saiko P; Illmer C; Madlener S; Hoechtl T; Bauer W; Erker T; Jaeger W; Fritzer-Szekeres M; Szekeres T
Exp Hematol; 2005 Mar; 33(3):329-35. PubMed ID: 15730856
[TBL] [Abstract][Full Text] [Related]
31. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
32. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
Yang LY; Li L; Jiang H; Shen Y; Plunkett W
Clin Cancer Res; 2000 Mar; 6(3):773-81. PubMed ID: 10741696
[TBL] [Abstract][Full Text] [Related]
33. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation.
Vrana JA; Kramer LB; Saunders AM; Zhang XF; Dent P; Povirk LF; Grant S
Biochem Pharmacol; 1999 Jul; 58(1):121-31. PubMed ID: 10403525
[TBL] [Abstract][Full Text] [Related]
35. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
Jiang HY; Hickey RJ; Abdel-Aziz W; Malkas LH
Cancer Chemother Pharmacol; 2000; 45(4):320-8. PubMed ID: 10755321
[TBL] [Abstract][Full Text] [Related]
36. Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
Cory AH; Hertel LW; Kroin JS; Cory JG
Oncol Res; 1993; 5(2):59-63. PubMed ID: 8364254
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells.
Graziadei I; Kelly T; Schirmer M; Geisen FH; Vogel W; Konwalinka G
J Hepatol; 1998 Mar; 28(3):504-9. PubMed ID: 9551690
[TBL] [Abstract][Full Text] [Related]
38. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
[TBL] [Abstract][Full Text] [Related]
39. Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.
Chen P; Aimiuwu J; Xie Z; Wei X; Liu S; Klisovic R; Marcucci G; Chan KK
AAPS J; 2011 Mar; 13(1):131-40. PubMed ID: 21191677
[TBL] [Abstract][Full Text] [Related]
40. Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture.
Matsumoto M; Tihan T; Cory JG
Cancer Chemother Pharmacol; 1990; 26(5):323-9. PubMed ID: 2208572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]